Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2023 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. I need to look for evidence in the transcript where management describes specific customers, partners, or programs that are already being served, and where those parties' own growth trajectories drive the company's forward outlook. Scanning the transcript, I see discussions about: - Asia sales growth, particularly Hong Kong and Mainland Chinese visitor customers - Canada affinity market sale (Ontario Medical Association) - Global WAM net flows - US business challenges The affinity sale in Canada is described as a large one-time sale (Ontario Medical Association, 36,000 customers, $150-160 million premium). This is described as a completed sale, not an ongoing trajectory of a counterparty's expansion. The Asia discussion mentions "return of demand from Mainland Chinese visitor customers" - this is a broad market condition, not a specific counterparty's own build-out or scaling. The US business discussion mentions launching a "multi life product" - that's the company's own product launch, not a counterparty's trajectory. There's no instance where management describes a specific customer, partner, or program that is already being served and whose own expansion plans drive the company's future results. The discussions are about the company's own sales, products, and market conditions. The answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.